Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
暂无分享,去创建一个
A. Meirovitz | A. Yakobson | W. Shalata | Ashraf Abu Jama | Ahron Yehonatan Cohen | Jeremy Zolnoorian | Y. Dudnik | Gabrielle Migliozzi
[1] O. A. Abu Saleh,et al. A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors , 2022, Cancers.
[2] N. Peled,et al. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience , 2022, Oncology.
[3] L. Evelson,et al. Applying methods of twin comparing quantitative and binary samples in biomedical information systems for decision making , 2022, Vestnik of Astrakhan State Technical University. Series: Management, computer science and informatics.
[4] A. Agbarya,et al. Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future , 2021, Journal of clinical medicine.
[5] A. Yakobson,et al. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review , 2021, Cancers.
[6] A. Agbarya,et al. Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future , 2021, Cancers.
[7] L. Sequist,et al. Lung cancer , 2021, The Lancet.
[8] A. Tafreshi,et al. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] A. Porgador,et al. Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma) , 2021, Cancers.
[10] A. Tafreshi,et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] N. Peled,et al. Associated Myocarditis: A Predictive Factor for Response? , 2020, Case Reports in Oncology.
[12] J. Weiss,et al. Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy. , 2020, Clinics in chest medicine.
[13] S. Novello,et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Gemma,et al. Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer , 2020, Thoracic cancer.
[15] S. Kimura,et al. Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer , 2019, Thoracic cancer.
[16] Jianying Zhou,et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.
[17] Yi-long Wu,et al. Emerging therapies for non-small cell lung cancer , 2019, Journal of Hematology & Oncology.
[18] A. Tafreshi,et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Presley,et al. Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults , 2017, Current Oncology Reports.
[20] I. Tabbara,et al. Immune-based Therapies for Non-small Cell Lung Cancer. , 2017, Anticancer research.
[21] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[22] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[23] L. Horn. Advances in the treatment of non-small cell lung cancer. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[24] D. Gerber,et al. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[26] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[27] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .